window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 29, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

phase 3 trial

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    ViiV Healthcare highlights ultra long-acting HIV pipeline and Phase 1 data at CROI 2026

    ViiV Healthcare will present new data from its long-acting and [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Compass Pathways reports positive second Phase 3 trial for COMP360 in treatment-resistant depression

    Compass Pathways has reported that its second pivotal Phase 3 [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Boehringer Ingelheim’s apecotrep reduces proteinuria in Phase 2 FSGS trial

    Boehringer Ingelheim has reported Phase 2 clinical trial results showing [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Scancell clears FDA IND for iSCIB1+ registrational Phase 3 trial in advanced melanoma

    Scancell Holdings has announced that the U.S. Food and Drug [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Bicara announces Phase 3 optimal dose for ficerafusp alfa and provides 2026 corporate outlook

    Bicara Therapeutics has selected 1500 mg of ficerafusp alfa as [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    FDA grants Fast Track designation to Enterome’s EO2463 immunotherapy in follicular lymphoma

    Doron Therapeutics has dosed the first patients in its Phase [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Enterome’s EO2463 receives FDA fast track designation for follicular lymphoma watch-and-wait treatment

    Enterome has received Fast Track designation from the US Food [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Cidara Therapeutics expands and accelerates phase 3 trial of CD388 for flu prevention

    Cidara Therapeutics has announced an expanded and accelerated Phase 3 [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Opinion & Events,Pharmaceuticals and therapeutics,Therapeutic Areas

    Saphnelo self-administration Phase 3 trial meets primary endpoint in systemic lupus erythematosus

    AstraZeneca has reported positive interim results from the Phase 3 [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Opinion & Events,Pharmaceuticals and therapeutics

    MaaT Pharma reports strong Phase 3 results and EMA submission for Xervyteg

    MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech focused on microbiome-based [...]

    May 5, 2026
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Novogene expands single-cell sequencing capability in Cambridge
    Categories: Genomics and sequencing, Research & Development
  • Femtosecond lasers could offer alternative to PFAS coatings
    Categories: Manufacturing & Supply Chain, Medical devices, Research & Development
  • CHMP recommends EU marketing authorisation for two obicetrapib treatments
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top